Quidel Corp
F:QL1
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Quidel Corp
NASDAQ:QDEL
|
1.9B USD |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
60B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.9T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
29.6B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
109.6B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.7B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
3.9B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.8B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Quidel Corp
Glance View
Quidel Corporation, a player in the diagnostic healthcare industry, has steadily navigated the labyrinth of medical innovation, carving out a niche in rapid diagnostic testing. Born out of a mission to streamline the process of disease detection, Quidel has leveraged biotechnology to develop fast, reliable diagnostic solutions that address widespread health issues. This company’s arsenal includes tests for infectious diseases, reproductive health, and autoimmune disorders—each meticulously designed to expedite the diagnostic process while maintaining a stringent commitment to accuracy. By fostering partnerships with healthcare providers and aligning with technological advancements, Quidel has positioned itself as indispensable in the clinic setting, where swift decision-making can significantly impact patient care. At the heart of Quidel's business model is its focus on providing tangible value to both healthcare professionals and patients. The company generates revenue primarily through the sale of its diagnostic products, which are utilized in settings ranging from small clinics to large hospital networks. Quidel's innovative platforms, like the Sofia and Solana systems, are lauded for their efficiency and ease of use, attributes that resonate particularly well in medical environments under pressure to deliver fast and effective results. By effectively converting scientific expertise into practical and user-friendly applications, Quidel not only enhances patient outcomes but also fortifies its financial standing within the competitive landscape of medical diagnostics.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Quidel Corp is 47.2%, which is below its 3-year median of 48.6%.
Over the last 3 years, Quidel Corp’s Gross Margin has decreased from 65.1% to 47.2%. During this period, it reached a low of 46.2% on Dec 29, 2024 and a high of 65.1% on Oct 2, 2022.